Treatment following progression on chemotherapy and an immune checkpoint inhibitor remains an unmet medical need.
Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses standard treatment for patients with metastatic urothelial cancer in the frontline setting and beyond.
